Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

and GLP-1 (glucagon-like peptide-1) hormone receptors which eventually help with obesity, overweight and type 2 diabetes. According to the company, the injection is supposed to be taken once every ...

More and more people are microdosing Ozempic, a popular weight loss drug, due to high costs and uncomfortable side effects.

Income Tax department has completed the regular assessment under Section 143(3) and passed assessment order pertaining to AY ...

MNC pharma major Eli Lilly has launched Mounjaro (tirzepatide), a weekly injection for obesity and ... sugar control in clinical trials. GLP-1, or glucagon-like peptide-1, are hormones produced ...

Ozempic (semaglutide) is a brand-name injection pen used to treat type ... glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Packaged as an injection, Mounjaro (tirzepatide ... called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. "Unlike conventional ...

Gvoke, Xeris’s ready-to-use glucagon therapy ... a once-weekly subcutaneous levothyroxine injection currently in phase 3 trials for hypothyroidism. If authorized, this treatment could fill ...

and GLP-1 (glucagon-like peptide-1) receptors, helping regulate blood sugar levels while promoting weight loss. The 2.5 mg dose is priced at Rs 3,500 per injection, with a monthly cost of Rs ...

Eli Lilly’s Mounjaro is a once-weekly injection approved by India’s drug ... phase and second phase insulin secretion, and reduces glucagon levels; it also improves insulin sensitivity and ...